Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
30 nov. 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
United States Regenerative Medicine Market Report 2023: Competition, Forecasts and Opportunities, 2018-2028
28 nov. 2023 09h53 HE
|
Research and Markets
Dublin, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
27 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells...
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
27 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
16 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA...
Regenerative Medicine Market Is Projected to Reach an Estimate of $83,196.72 Million by 2030: Allied Market Research
14 nov. 2023 10h51 HE
|
Allied Market Research
Wilmington, Delaware, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Regenerative Medicine Market by Product Type (Gene Therapy, Cell Therapy, Tissue...
Immatics Announces Third Quarter 2023 Financial Results and Business Update
14 nov. 2023 07h00 HE
|
https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
09 nov. 2023 21h49 HE
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
09 nov. 2023 06h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
08 nov. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is...